JP2005041807A - Oral drug containing amino acid for preventing and treating hay fever - Google Patents

Oral drug containing amino acid for preventing and treating hay fever Download PDF

Info

Publication number
JP2005041807A
JP2005041807A JP2003202227A JP2003202227A JP2005041807A JP 2005041807 A JP2005041807 A JP 2005041807A JP 2003202227 A JP2003202227 A JP 2003202227A JP 2003202227 A JP2003202227 A JP 2003202227A JP 2005041807 A JP2005041807 A JP 2005041807A
Authority
JP
Japan
Prior art keywords
hay fever
amino acid
amino acids
weight
test
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003202227A
Other languages
Japanese (ja)
Inventor
Masaru Otani
勝 大谷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Priority to JP2003202227A priority Critical patent/JP2005041807A/en
Publication of JP2005041807A publication Critical patent/JP2005041807A/en
Pending legal-status Critical Current

Links

Abstract

<P>PROBLEM TO BE SOLVED: To obtain a drug for preventing and treating hay fever, which has no side effect and is capable of improving physical conditions. <P>SOLUTION: An amino acid composition effective for preventing and treating hay fever contains two or five specified amino acids as its active ingredients in prescribed proportions. <P>COPYRIGHT: (C)2005,JPO&NCIPI

Description

【0001】
【発明の属する技術分野】
本発明は、有効成分として特定のアミノ酸を特定の割合で含有する花粉症の予防治療に有効なアミノ酸組成物、すなわち、(a)2種のアミノ酸を有効成分として含有する、L−アルギニン及びL−グルタミンを有効成分として、前者1重量部に対し後者0.25〜4重量部の割合で含有することを特徴とする経口アミノ酸花粉症予防治療剤、及び(b)前記2種のアミノ酸を含む5種のアミノ酸を有効成分として含有する、L−アルギニン、L−グルタミン、L−バリン、L−イソロイシンおよびL−ロイシンの5種のアミノ酸を、それぞれ、10〜40重量部、10〜40重量部、5〜20重量部、8〜30重量部および10〜35重量部の割合で含有することを特徴とする経口アミノ酸花粉症予防治療剤に関する。
【0002】
【従来の技術】
【特許文献1】特開2002−3372号公報
前年まで花粉症を発症したことがなかったのに、ある年初めて花粉症を発症し、以後毎年発症するというように、近年、どういうわけか花粉症に悩まされる者が増加しつつある。
【0003】
因みに、花粉症に関しては、例えば、「花粉症 花粉症は花粉に感作された個体が原因花粉に暴露されることにより発症するI型アレルギーによる疾患である。毎年ほぼ同じ時期に花粉の飛散時期に一致して症状が出現しはじめ、花粉の飛散量の増加と共に症状が増悪し、その時期が過ぎると症状が突然消失するのが普通である。鼻粘膜、鼻汁中に存在するマスト細胞(肥満細胞)、好塩基球の細胞膜上の特異的IgE抗体と花粉抗原との反応の結果遊離されるヒスタミン、slow−reacting substance of anaphylaxis(SRS−A;ロイコトリエンC、D、E)などの化学伝達物質により症状が発現する。欧米では枯草熱ともいわれている。本症は鼻アレルギー、アレルギー性結膜炎、気管支喘息のさまざまな組み合わせで起こる。花粉症の原因となる植物はスギ、ヒノキ、サワラなどの樹木、かもガヤ、オオアワガエリ、ナガハグサなどのイネ科植物、ブタクサ、ヨモギ、カナムグラなどの雑草類である。症状としては大量の水性鼻漏、鼻閉、くしゃみ、鼻内掻痒などの鼻アレルギーの症状、眼結膜の発赤、掻痒、流涙、眼瞼腫脹などのアレルギー性結膜炎の症状、呼吸困難、喘鳴、せきなどの気管支喘息の症状がみられる。」と解説されているように(「医学大辞典」(南山堂1998年発行第18版))、その症状は極めて不快であり、かつ発症者によっては重大な影響を受ける。
【0004】
このような花粉症の予防治療法としては、従来抗アレルギー薬の摂取や神経ブロックなどの対処法があった。
【0005】
しかしながら、これらの方法には、効果面であるいは眠気等の副作用の面で問題があり、さらなる優れた対処法の開発が切望されている。
【0006】
さて、本発明者は、多年各種アミノ酸類の栄養作用や生理作用の研究に従事し、その間、特定のアミノ酸の特定の割合の組成物が栄養状態の改善に有効なことを見出し(前掲特許文献1)、あるいはまた育毛作用に優れることを見出している(特願2002−211003)。しかしながら、花粉症に対してアミノ酸が効果があるという知見はなかった。
【0007】
【発明が解決しようとする課題】
前項記載の従来技術の背景下に、本発明は前記のような副作用がないのみならず、体調も改善できると言う特長を有する花粉症の予防治療剤を提供することを目的とする。
【0008】
【課題を解決するための手段】
本発明者は、先に説明したように、各種アミノ酸類の栄養作用や生理作用の研究に長年従事してきたところ、前掲特許文献1や前掲特願2002−211003に開示されているところと同様に、特定のアミノ酸を特定の割合で経口摂取すれば花粉症の予防治療に有効であることを見出し、このような知見に基づいて本発明を完成した。
【0009】
すなわち、本発明は、先に説明したように、有効成分として特定のアミノ酸を特定の割合で含有する花粉症の予防治療に有効なアミノ酸組成物、すなわち、(a)2種のアミノ酸を有効成分として含有する、L−アルギニン及びL−グルタミンを有効成分として、前者1重量部に対し後者0.25〜4重量部の割合で含有することを特徴とする経口アミノ酸花粉症予防治療剤、及び(b)前記2種のアミノ酸を含む5種のアミノ酸を有効成分として含有する、L−アルギニン、L−グルタミン、L−バリン、L−イソロイシンおよびL−ロイシンの5種のアミノ酸を、それぞれ、10〜40重量部、10〜40重量部、5〜20重量部、8〜30重量部および10〜35重量部の割合で含有することを特徴とする経口アミノ酸花粉症予防治療剤に関する。
【0010】
因みに、両者のなかでは、アミノ酸のバランスという栄養学的見地からするとL−アルギニン及びL−グルタミンに加えてL−バリン、L−イソロイシン及びL−ロイシンをも加えた後者の5種のアミノ酸を有効成分として含有するものが好ましい。
【0011】
【発明の実施の形態】
以下、本発明を詳細に説明する。
【0012】
本発明の経口アミノ酸花粉症予防治療剤の調製には特別の制限や困難はなく、所定のアミノ酸を所定の割合で含有せしめることを除いては、適宜常法に準ずることができる。
【0013】
本発明の経口アミノ酸花粉症予防治療剤は、上記所定の2種又は5種のアミノ酸を上記所定の割合で単に混合して調製する他に、適宜の添加剤を使用して常法により調製することもできる。このような添加剤としては、味を調整改良する果汁、デキストリン、環状オリゴ糖、糖類(果糖ぶどう糖液糖、ショ糖)、酸味料、香料、抹茶粉末など、テクスチャーを改善する乳化剤、コラーゲン、全脂粉乳、増粘多糖類や寒天(ゼリー飲料の場合)など、更には前記2種又は5種のアミノ酸以外のアミノ酸、ビタミン類、卵殻カルシウム、パントテン酸カルシウム、その他のミネラル類、ローヤルゼリー、プロポリス、蜂蜜、食物繊維、アガリクス、キチン、キトサン、漢方生薬、コンドロイチン、カプサイシンなどの通常健康食品の成分として使用されているものを挙げることができる。
【0014】
本発明の経口アミノ酸花粉症予防治療剤の製品形態には特別の制限はなく、経口摂取(摂食)できる形態であればいずれの形態でもよい。このような形態としては、適当な賦形剤を使用した粉末、顆粒、タブレット、液体(飲料、ゼリー飲料など)、キャンディ(チョコレートなど)等を挙げることができる。製品形態の極端な場合としては、上記2種又は5種のアミノ酸の上記割合の単なる粉体混合物(粉末)を挙げることができる。粉末の場合は、直接粉薬のようにそのまま水で飲んでもよいし、またオブラートに包んで飲むこともでき、あるいは水、牛乳、ジュースなどに溶解して飲むこともできる。
【0015】
本発明による花粉症予防治療効果は、後記実験例1の結果を考慮して、必須成分である2種のアミノ酸を上記割合で1日当りの合計で2g以上、また5種のアミノ酸の場合は、上記割合で1日当りの合計で3g以上摂取することで奏せしめ得る。これより少量では目的の効果が奏されない。一方、過剰に摂取しても効果の向上は見込まれないので、1日当りの摂取量は2種の場合で最大約10g、そして5種の場合で最大約16gとすることができる。このような範囲に含まれる量として、例えば、後掲実験例1にみられる10g程度/日を好ましい量として挙げることができる。従って、本発明の経口アミノ酸花粉症予防治療剤の製品における必須成分であるアミノ酸の含有量は、1日当りの摂取回数も考慮して、適宜このような摂取量を満足せしめることのできる量とすればよい。
【0016】
【実施例】
以下、試験例により本発明を更に詳細に説明する。
【0017】
試験例1(花粉症患者に対するアミノ酸投与試験)
(1)試験の概要:
(a)花粉症患者を対象に、アミノ酸摂取による花粉症症状に対する有用性を検討した。
【0018】
(b)被験者は、年齢23歳から47歳の10名で平均年齢32.3歳であり、自己申告による花粉症症状の程度は、重症が1名、中等症が4名、軽症が5名であった。
【0019】
(c)試験は、1日4回毎食後及び就寝前に「アミノバイタル毎日いきいき」を1袋ずつ(1日量:前記5種のアミノ酸5.2g)及び「ウォーターチャージ500ml」2本(1日量:アミノ酸2g)を16週間摂取し、試験開始前、4週間後、8週間後、12週間後、16週間後に来院し、鼻腔所見及び血液検査(血液一般、IgE−RIST、HRTスコア)及び鼻汁検査(好酸球数)を行った。
【0020】
(d)(i)HRTスコアからスギHRT陽性でスギ花粉症であると診断された5例のうち、下鼻甲介の腫脹は改善したものが2例、不変だったものが2例、一段階増悪したものの再び改善したものが1例認められ、鼻汁の量は改善したものが2例、不変だったものが2例、一段階増悪したものの再び改善したものが1例認められた。(ii)スギHRT陰性で通年性アレルギー性鼻炎の原因であるヤケヒョウダニに対する抗体陽性例1例については、下鼻甲介の腫脹は投与開始4週目で二段階改善したものの12週目には再び一段階増悪し、鼻汁の量は投与8週間目一段階増悪したものの12週目には一段階改善した。(iii)スギHRT陰性でヤケヒョウダニ陰性例4例のうち、下鼻甲介の腫脹は改善したものが1例、不変だったものが1例、一段階増悪したものの再び改善したものが1例、一段階増悪したものが1例認められ、鼻汁の量は改善したもの1例、不変だったものが1例、一段階増悪したものの再び改善したものが2例認められた。
【0021】
(e)以上の結果から、例年であれば花粉症の症状が悪化するのに対し、鼻腔所見、鼻汁の量ともにアミノ酸摂取前(某年12月)と大きな変化が認められず、本発明の経口アミノ酸花粉症予防治療剤の効果は良好であるとの印象を得た(翌年4月11日)。
【0022】
(f)試験終了後の被験者アンケートについては、例年の花粉症症状と比較して、症状(くしゃみ、鼻水、鼻閉、目の痒み、生活支障度)は軽く、薬量は少なく、アミノ酸摂取による花粉症症状改善に対する有用性を感じているという良好な評価が得られた。また、試験終了時よりも摂取中止1週間後の方が、各症状が悪化しているという傾向が見られた。スギ花粉飛散量は試験終了時から大幅に減少してはいるものの、摂取中止1週間後も花粉は飛散していた。
【0023】
(2)試験の詳細:
(a)被験者(モニター):下記第1表に示す。
【0024】
【表1】

Figure 2005041807
【0025】
(b)試験のスケジュール:試験製品の摂取期間は16週間とし、被験者は、下記第2表に示すスケジュールにて試験を行うものとした。
【0026】
【表2】
Figure 2005041807
【0027】
(c)供試製品の服用方法:
供試製品は、1日4回毎食後及び就寝前にアミノ酸製剤「アミノバイタル毎日いきいき」を1袋づつ(1日量:前記5種のアミノ酸5.2g)及びスポーツドリンク「ウォーターチャージ500ml」2本(1日量:アミノ酸2g)を摂取するものとした。
【0028】
ここに、アミノ酸製剤「アミノバイタル毎日いきいき」及びスポーツドリンク「ウォーターチャージ500ml」はいずれも、味の素(株)の販売にかかるもので、前者は、1袋3g中、前記5種のアミノ酸を計1.3gを含み、それらのアミノ酸の重量比は、L−アルギニン 26:L−グルタミン 26:L−バリン 14:L−イソロイシン 14:L−ロイシン 20であった。また、後者は、1本500ml中、4種のアミノ酸を計1g含み、それらのアミノ酸の重量比は、L−アルギニン 30:L−バリン 19:L−ロイシン 28:L−イソロイシン 23であった。
【0029】
(d)鼻腔所見及び被験者日誌及び検査項目:
(i)鼻腔所見:各来院日に、鼻汁の量、甲介の腫脹の程度について、次の3段階で判定した:すなわち、0:なし、1:軽度、2:高度。
【0030】
(ia)また、EVIS鼻咽喉ビデオスコープ(ENF P200/T200:OLYMPUS社)にて、鼻腔内を観察した。
【0031】
(ii)被験者日誌:くしゃみ発作、鼻汁、鼻閉、眼症状、日常生活支障度についてスコア化し、症状の変化を観察した。
【0032】
(iii)検査:各来院日に、血液検査(血液一般、IgE−RIST、HRTスコア)及び鼻汁検査(好酸球数)を行った。
【0033】
(e)試験結果:
(i)被験者の背景:本試験被験者の背景を下記第3表にまとめた。年齢は、23歳から47歳の10名で平均年齢32.3歳であった。自己申告による花粉症症状の程度は、重症が1名、中等症が4名、そして軽症が5名であった。
【0034】
【表3】
Figure 2005041807
【0035】
(ii)鼻腔所見:鼻腔所見を下記第4表にまとめた。
【0036】
【表4】
Figure 2005041807
【0037】
【表5】
Figure 2005041807
【0038】
第4表から得られる知見については、上記の(1)試験の概要の(d)に前述した。
【0039】
また、医師による症状の聴き取りからは、「症状が例年より軽い」、「生活支障度が低い」、「薬量が減少した」等の花粉症症状に対する被験者コメントが得られ、その他体調及び肌状態が良くなった等のコメントが得られた。
【0040】
(iii)鼻汁検査(好酸球数)、IgE−RIST、HRTスコア:鼻汁検査(好酸球数)、IgE−RIST、HRTスコアのデータから、スギHRT陽性でスギ花粉症であると診断されたものが5例認められ、スギHRT陰性で通年性アレルギー性鼻炎の原因であるヤケヒョウダニに対する抗体陽性例が1例認められ、スギHRT陰性でヤケヒョウダニ陰性例が4例認められた。
【0041】
(iv)被験者評価:試験終了後及び摂取中止1週間後の被験者アンケート結果を下記第5表に、被験者コメントを下記第6表にまとめた。例年の花粉症症状と比較して、症状(くしゃみ、鼻水、鼻閉、眼の痒み、生活支障度)は軽く、薬量は少なく、アミノ酸摂取による花粉症症状改善に対する有用性を感じているという良好な評価が得られた。また、試験終了時よりも摂取中止1週間後の方が、各症状が悪化しているという傾向が見られた。
【0042】
【表6】
Figure 2005041807
【0043】
【表7】
Figure 2005041807
【0044】
試験例2(2種アミノ酸の摂取試験)
男女合計10人にアミノ酸としてL−アルギニンおよびL−グルタミンを合計1g含有する混合物(L−アルギニンとL−グルタミンの割合は6:4(重量比)。これらのアミノ酸以外にL−アラニン、西洋人参エキス、酸味料等を含有。)を1日3回摂取したところ、例年の花粉症が軽減されたことは下記第7表に示す通りである。
【0045】
【表8】
Figure 2005041807
【0046】
試験例1および試験例2の結果を総合的に考察したところ、体感調査から体調及び肌の状態がよくなった等のコメントが5種アミノ酸摂取グループにのみあったことから有効アミノ酸成分として5種のアミノ酸を含有する組成物が2種のアミノ酸を含有する組成物に優れることが判る。
【0047】
【発明の効果】
本発明によれば、副作用のない、しかも体調を改善できる花粉症の予防治療剤が容易に提供することができる。[0001]
BACKGROUND OF THE INVENTION
The present invention relates to an amino acid composition effective for the prevention and treatment of hay fever containing a specific amino acid in a specific ratio as an active ingredient, that is, (a) L-arginine and L containing two amino acids as active ingredients -Containing glutamine as an active ingredient in an amount of 0.25 to 4 parts by weight of the latter with respect to 1 part by weight of the former, and an oral amino acid hay fever preventive and therapeutic agent, and (b) containing the above two amino acids 5 kinds of amino acids containing 5 kinds of amino acids as active ingredients, L-arginine, L-glutamine, L-valine, L-isoleucine and L-leucine, 10-40 parts by weight, 10-40 parts by weight, respectively , 5 to 20 parts by weight, 8 to 30 parts by weight, and 10 to 35 parts by weight.
[0002]
[Prior art]
[Patent Document 1] Japanese Patent Application Laid-Open No. 2002-3372 In the recent years, hay fever has been developed for the first time in a certain year, but has been developed every year thereafter. The number of people suffering from is increasing.
[0003]
For example, regarding hay fever, for example, “hay fever hay fever is a disease caused by type I allergy that occurs when an individual sensitized to pollen is exposed to the pollen. Symptoms usually begin to appear, and as the amount of pollen increases, the symptoms usually abruptly disappear, and mast cells present in the nasal mucosa and nasal discharge (obesity) Cells), histamine released as a result of the reaction between specific IgE antibody on the cell membrane of basophils and pollen antigen, slow-reacting maintenance of anaphylaxis (SRS-A; leukotrienes C 4 , D 4 , E 4 ), etc. Symptoms are manifested by chemical mediators, also called hay fever in Europe and the US This disease is a nasal allergy, allergic conjunctivitis, bronchial asthma Plants that cause hay fever are trees such as cedar, cypress, and sawara, grasses such as gaya, green moth, and nagahagus, and weeds such as ragweed, mugwort, and humminggrass. As a symptom of nasal allergies such as massive aqueous rhinorrhea, nasal congestion, sneezing, intranasal itching, allergic conjunctivitis symptoms such as redness of the eye conjunctiva, pruritus, lacrimation, eyelid swelling, dyspnea, wheezing, coughing, etc. As it is explained ("Medical Dictionary" (Nanzan-do 1998, 18th edition)), the symptoms are extremely unpleasant and may be serious depending on the person who develops the disease. to be influenced.
[0004]
Conventionally, there have been countermeasures such as ingestion of antiallergic drugs and nerve block as preventive treatments for such pollinosis.
[0005]
However, these methods have problems in terms of effects or side effects such as drowsiness, and the development of further excellent countermeasures is eagerly desired.
[0006]
Now, the present inventor has been engaged in research on nutritional and physiological effects of various amino acids for many years, and during that time, it has been found that a composition of a specific ratio of specific amino acids is effective in improving the nutritional state (see the above-mentioned patent document). 1), or has also been found to be excellent in hair-growth action (Japanese Patent Application No. 2002-211003). However, there was no finding that amino acids were effective against hay fever.
[0007]
[Problems to be solved by the invention]
In view of the background of the prior art described in the preceding paragraph, an object of the present invention is to provide a preventive / therapeutic agent for hay fever, which has the feature that not only the side effects as described above but also the physical condition can be improved.
[0008]
[Means for Solving the Problems]
As described above, the present inventor has been engaged in the research on the nutritional and physiological effects of various amino acids for many years, and as described in the above-mentioned Patent Document 1 and the above-mentioned Japanese Patent Application No. 2002-211003. The inventors have found that if a specific amino acid is orally ingested at a specific ratio, it is effective for the prevention and treatment of hay fever, and the present invention has been completed based on such findings.
[0009]
That is, as described above, the present invention provides an amino acid composition effective for the prevention and treatment of hay fever containing a specific amino acid in a specific ratio as an active ingredient, that is, (a) two kinds of amino acids as active ingredients. L-arginine and L-glutamine contained as active ingredients in an amount of 0.25 to 4 parts by weight of the latter with respect to 1 part by weight of the former, and b) 5 types of amino acids including L-arginine, L-glutamine, L-valine, L-isoleucine and L-leucine containing 5 types of amino acids including the 2 types of amino acids as active ingredients, 40 parts by weight, 10 to 40 parts by weight, 5 to 20 parts by weight, 8 to 30 parts by weight and 10 to 35 parts by weight On.
[0010]
By the way, in both cases, from the nutritional point of view of the balance of amino acids, the latter five amino acids are effective in which L-valine, L-isoleucine and L-leucine are added in addition to L-arginine and L-glutamine. What is contained as a component is preferable.
[0011]
DETAILED DESCRIPTION OF THE INVENTION
Hereinafter, the present invention will be described in detail.
[0012]
There are no particular restrictions or difficulties in the preparation of the oral amino acid hay fever preventive / therapeutic agent of the present invention, and it can be applied according to conventional methods as appropriate, except that a predetermined amino acid is contained in a predetermined ratio.
[0013]
The oral amino acid hay fever preventive / therapeutic agent of the present invention is prepared by a conventional method using appropriate additives in addition to the above-mentioned predetermined two or five amino acids simply mixed at the predetermined ratio. You can also. Such additives include fruit juice, dextrin, cyclic oligosaccharides, sugars (fructose glucose liquid sugar, sucrose), acidulants, fragrances, powdered green tea powder, emulsifiers that improve texture, collagen, all Fat milk powder, thickening polysaccharides, agar (in the case of jelly drinks), amino acids other than the above 2 or 5 amino acids, vitamins, calcium eggshell, calcium pantothenate, other minerals, royal jelly, propolis, Examples include honey, dietary fiber, agaricus, chitin, chitosan, herbal medicine, chondroitin, capsaicin, and the like that are usually used as components of health foods.
[0014]
The product form of the agent for preventing and treating oral amino acid hay fever of the present invention is not particularly limited, and any form may be used as long as it can be taken orally (taken). Examples of such forms include powders, granules, tablets, liquids (such as beverages and jelly beverages), and candy (such as chocolates) using appropriate excipients. As an extreme case of the product form, a simple powder mixture (powder) of the above-mentioned ratio of the above-mentioned two or five amino acids can be mentioned. In the case of powder, it can be taken directly with water like a powder, or it can be taken by wrapping in an oblate, or it can be taken by dissolving in water, milk, juice or the like.
[0015]
The effect of preventing and treating hay fever according to the present invention is as follows. In consideration of the results of Experimental Example 1 to be described later, the above-mentioned ratio of 2 amino acids as essential components is 2 g or more in total per day, and in the case of 5 amino acids, It can be achieved by ingesting 3 g or more in total at the above rate per day. If the amount is less than this, the desired effect is not achieved. On the other hand, since the effect is not expected to be increased even if it is excessively consumed, the daily intake can be about 10 g at the maximum in the case of 2 types and about 16 g at the maximum in the case of 5 types. As an amount included in such a range, for example, about 10 g / day seen in Experimental Example 1 described below can be cited as a preferable amount. Therefore, the content of the amino acid, which is an essential component in the product for preventing and treating oral amino acid hay fever of the present invention, should be an amount that can satisfy such an intake as appropriate in consideration of the number of intakes per day. That's fine.
[0016]
【Example】
Hereinafter, the present invention will be described in more detail with reference to test examples.
[0017]
Test Example 1 (Amino acid administration test for hay fever patients)
(1) Outline of the test:
(A) In patients with hay fever, the usefulness of the amino acid intake for hay fever symptoms was examined.
[0018]
(B) The subjects were 10 people aged 23 to 47, with an average age of 32.3 years. The self-reported degree of hay fever was 1 for severe, 4 for moderate, and 5 for mild. Met.
[0019]
(C) The test consisted of 1 bag of “Amino Vital Daily Lively” after each meal and before going to bed 4 times a day (daily amount: 5.2 g of the above five amino acids) and 2 “water charge 500 ml” (1 day Amount: Amino acid 2g) was taken for 16 weeks, before the start of the study, 4 weeks, 8 weeks, 12 weeks, 16 weeks later, nasal findings and blood tests (blood in general, IgE-RIST, HRT score) and A nasal discharge test (eosinophil count) was performed.
[0020]
(D) (i) Of the 5 cases diagnosed as cedar HRT positive and cedar pollinosis based on the HRT score, 2 cases improved swelling of the inferior turbinates, 2 cases remained unchanged, 1 stage There was one case that had worsened but improved again, two cases that improved the amount of nasal discharge, two cases that remained unchanged, and one case that worsened one step and improved again. (Ii) In one case of antibody positive against a mushroom mite that is negative for cedar HRT and causes perennial allergic rhinitis, the swelling of the lower turbinates improved in two stages at the fourth week of administration, but again at 12 weeks The stage worsened and the amount of nasal discharge worsened by one stage at the eighth week of administration, but improved by one stage at the 12th week. (Iii) Among 4 cases of cedar HRT negative and discolored mushroom mite negative, one case improved swelling of inferior turbinates, 1 case remained unchanged, 1 case worsened once but worsened, 1 case One case was found to have deteriorated in stages, 1 case in which the amount of nasal discharge was improved, 1 case in which the amount of nasal discharge was unchanged, 1 case in which the amount of nasal discharge was unchanged, and 2 cases in which deterioration was made once but improved.
[0021]
(E) From the above results, although the symptoms of hay fever are aggravated in the usual years, the nasal findings and the amount of nasal discharge are not significantly different from those before ingestion of amino acids (December 2001). The impression that the effect of the oral amino acid pollinosis preventive and therapeutic agent was good was obtained (April 11, the following year).
[0022]
(F) About the subject questionnaire after the end of the study, the symptoms (sneezing, runny nose, nasal congestion, itchy eyes, difficulty of life) are lighter, the dosage is lower, and the intake of amino acids is compared to the usual hay fever symptoms A good evaluation was felt that it was useful for improving hay fever symptoms. Moreover, the tendency for each symptom to get worse was seen one week after the discontinuation of intake than at the end of the test. Although the amount of cedar pollen scattered significantly decreased from the end of the test, pollen was scattered even one week after stopping the intake.
[0023]
(2) Test details:
(A) Subject (monitor): as shown in Table 1 below.
[0024]
[Table 1]
Figure 2005041807
[0025]
(B) Test schedule: The intake period of the test product was 16 weeks, and the subjects were to perform the test according to the schedule shown in Table 2 below.
[0026]
[Table 2]
Figure 2005041807
[0027]
(C) How to take the test product:
The test product is 4 amino acids after every meal and before going to bed one amino acid preparation “Amino Vital Daily Ikiiki” (1 daily dose: 5.2 g of the above 5 amino acids) and 2 sports drinks “Water Charge 500 ml” (Daily dose: 2 g of amino acid) was taken.
[0028]
Here, both the amino acid preparation “Amino Vital Daily Ikiiki” and the sports drink “Water Charge 500 ml” are related to the sales of Ajinomoto Co., Inc. 3 g were included, and the weight ratio of these amino acids was L-arginine 26: L-glutamine 26: L-valine 14: L-isoleucine 14: L-leucine 20. The latter contained 1 g of 4 kinds of amino acids in 500 ml each, and the weight ratio of these amino acids was L-arginine 30: L-valine 19: L-leucine 28: L-isoleucine 23.
[0029]
(D) Nasal findings, subject diary and examination items:
(I) Nasal findings: On each visit day, the amount of nasal discharge and the degree of swelling of the concha were determined in the following three stages: 0: none, 1: mild, 2: high.
[0030]
(Ia) The inside of the nasal cavity was observed with an EVIS nasopharyngeal videoscope (ENF P200 / T200: OLYMPUS).
[0031]
(Ii) Subject diary: scored for sneezing seizures, nasal discharge, nasal congestion, ocular symptoms, and difficulty in daily life, and observed changes in symptoms.
[0032]
(Iii) Examination: On each visit day, a blood test (blood in general, IgE-RIST, HRT score) and a nasal discharge test (eosinophil count) were performed.
[0033]
(E) Test results:
(I) Background of test subjects: The background of the test subjects was summarized in Table 3 below. The average age was 32.3 years old with 10 people aged 23 to 47 years. The degree of hay fever symptoms by self-report was 1 for severe, 4 for moderate, and 5 for mild.
[0034]
[Table 3]
Figure 2005041807
[0035]
(Ii) Nasal findings: The nasal findings are summarized in Table 4 below.
[0036]
[Table 4]
Figure 2005041807
[0037]
[Table 5]
Figure 2005041807
[0038]
The knowledge obtained from Table 4 was described above in (d) of the outline of the test (1).
[0039]
In addition, listening to symptoms by doctors provided subject comments on hay fever symptoms such as “symptoms are lighter than usual”, “low disability”, “dose decreased”, and other physical and skin conditions. Comments such as better condition were obtained.
[0040]
(Iii) Nasal discharge test (eosinophil count), IgE-RIST, HRT score: From nasal discharge test (eosinophil count), IgE-RIST, HRT score data, cedar HRT positive and cedar pollinosis was diagnosed 5 cases were observed, one case of antibody positive against the dust mite that was negative for cedar HRT and causing perennial allergic rhinitis was found, and 4 cases of negative for cedar HRT and negative for dust mite were found.
[0041]
(Iv) Subject evaluation: Subject questionnaire results after completion of the test and one week after discontinuation of intake are summarized in Table 5 below, and subject comments are summarized in Table 6 below. Compared to the usual hay fever symptoms, the symptoms (sneezing, runny nose, nasal congestion, itchy eyes, difficulty in living) are light, the dosage is low, and I feel that it is useful for improving hay fever symptoms by taking amino acids Good evaluation was obtained. Moreover, the tendency for each symptom to get worse was seen one week after the discontinuation of intake than at the end of the test.
[0042]
[Table 6]
Figure 2005041807
[0043]
[Table 7]
Figure 2005041807
[0044]
Test Example 2 (Two amino acids intake test)
A mixture containing a total of 1 g of L-arginine and L-glutamine as amino acids for a total of 10 men and women (ratio of L-arginine and L-glutamine is 6: 4 (weight ratio). In addition to these amino acids, L-alanine, Western ginseng As shown in Table 7 below, ingestion of extract, acidulant, etc.) was taken 3 times a day, and the annual hay fever was reduced.
[0045]
[Table 8]
Figure 2005041807
[0046]
When the results of Test Example 1 and Test Example 2 were comprehensively examined, there were only 5 types of effective amino acid components as comments from only the 5 types of amino acid intake group that the physical condition and skin condition were improved from the sensory survey. It can be seen that a composition containing these amino acids is superior to a composition containing two amino acids.
[0047]
【The invention's effect】
ADVANTAGE OF THE INVENTION According to this invention, the prophylactic / therapeutic agent of hay fever which has no side effect and can improve a physical condition can be provided easily.

Claims (2)

有効成分として、L−アルギニン及びL−グルタミンを前者1重量部に対し後者0.25〜4重量部の割合で含有することを特徴とする経口アミノ酸花粉症予防治療剤。An oral amino acid hay fever preventive and therapeutic agent comprising L-arginine and L-glutamine as active ingredients in a proportion of 0.25 to 4 parts by weight of the latter with respect to 1 part by weight of the former. 有効成分として、L−アルギニン、L−グルタミン、L−バリン、L−イソロイシンおよびL−ロイシンの5種のアミノ酸を、それぞれ、10〜40重量部、10〜40重量部、5〜20重量部、8〜30重量部および10〜35重量部の割合で含有することを特徴とする経口アミノ酸花粉症予防治療剤。As an active ingredient, L-arginine, L-glutamine, L-valine, L-isoleucine and L-leucine, 5 types of amino acids, 10-40 parts by weight, 10-40 parts by weight, 5-20 parts by weight, An oral amino acid hay fever preventive and therapeutic agent, comprising 8 to 30 parts by weight and 10 to 35 parts by weight.
JP2003202227A 2003-07-28 2003-07-28 Oral drug containing amino acid for preventing and treating hay fever Pending JP2005041807A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2003202227A JP2005041807A (en) 2003-07-28 2003-07-28 Oral drug containing amino acid for preventing and treating hay fever

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003202227A JP2005041807A (en) 2003-07-28 2003-07-28 Oral drug containing amino acid for preventing and treating hay fever

Publications (1)

Publication Number Publication Date
JP2005041807A true JP2005041807A (en) 2005-02-17

Family

ID=34262007

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003202227A Pending JP2005041807A (en) 2003-07-28 2003-07-28 Oral drug containing amino acid for preventing and treating hay fever

Country Status (1)

Country Link
JP (1) JP2005041807A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009249323A (en) * 2008-04-04 2009-10-29 Nisshin Pharma Inc Antihistamine composition

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009249323A (en) * 2008-04-04 2009-10-29 Nisshin Pharma Inc Antihistamine composition

Similar Documents

Publication Publication Date Title
JP2009502958A (en) How to treat or manage stress
US10028991B2 (en) Composition, and method of using the composition, effective for minimizing the harmful effects associated with individuals suffering from alcohol intoxication
KR20060047367A (en) Composition trapping radicals in organism
CN112715729A (en) Blueberry lutein ester tablet candy for relieving visual fatigue and preparation method thereof
JP2006008568A (en) IgE ANTIBODY-SUPPRESSING AGENT AND FOOD
JP3665852B2 (en) Anti-atopic dermatitis composition
TWI605813B (en) Eye fatigue inhibiting composition and food and drink containing the same
WO2014010658A1 (en) Preparation containing indian long pepper
EP3100737A1 (en) Dietary supplement comprising a mixture of magnesium oxide and magnesium carbonate
JP2005041807A (en) Oral drug containing amino acid for preventing and treating hay fever
US20140170128A1 (en) Compositions for the management of glycated hemoglobin and blood glucose
US20120178799A1 (en) Energy beverage with creatine and caffeine combination
CN105616581A (en) Glipizide-containing pharmaceutical composition for treating diabetes and preparation method thereof
BE1026122B1 (en) Composition for preventing or reducing the effects of alcohol poisoning
JP2003159028A (en) Food for curing pollinosis
JP2004173589A (en) Food for ameliorating or preventing pollinosis
JP4577998B2 (en) Uric acid level lowering agent
JP6533784B2 (en) Eye fatigue improver
WO2024029620A1 (en) Cerebral blood flow augmenter, brain activity promoter, and wakefulness improver
JP6378926B2 (en) Composition for lowering blood glucose level
AU2003275847B2 (en) Sexual desire and performance enhancement with meal from plants containing protein-bound tryptophan
JPH0669352B2 (en) Foods for improving constitution
WO2022048634A1 (en) Preparation method for anti-inflammatory and kidney-protecting clam peptide and application of clam peptide
JP4836044B2 (en) Oral amino acid acne treatment
US20030219432A1 (en) Activated charcoal based composition and method for reducing hangover symptoms associated with the consumption of alcohol containing beverages

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Effective date: 20050523

Free format text: JAPANESE INTERMEDIATE CODE: A131

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20050902

A521 Written amendment

Effective date: 20051101

Free format text: JAPANESE INTERMEDIATE CODE: A523

RD04 Notification of resignation of power of attorney

Effective date: 20060202

Free format text: JAPANESE INTERMEDIATE CODE: A7424

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060227

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060425

A131 Notification of reasons for refusal

Effective date: 20060922

Free format text: JAPANESE INTERMEDIATE CODE: A131

A521 Written amendment

Effective date: 20061121

Free format text: JAPANESE INTERMEDIATE CODE: A523

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20070402